Omada was named to the 2026 Deloitte Technology Fast 500™, a ranking of the fastest-growing tech companies in North America, based on revenue growth from 2022 to 2025.
@seanduffy, our co-founder and CEO, and our Senior Director and Controller, accepted the recognition at the award celebration in San Francisco this week.
Thank you to the customers who bring our programs to their members, the members who put their trust in us, and the Omada team who built those programs and keep making them better. #Fast500
deloitte.com/us/en/services/…
Customer success drives our growth.📈
Our GLP-1 members lost ~2x more weight and retained 3x more muscle mass, with the potential to unlock thousands of dollars in savings in the long run.
When Omada members win, we win.
$OMDA
2
9
597
Members who struggle with cravings or emotional eating were more likely to build a meal-tracking habit with real-time AI feedback from Meal Map. New research from our team at #ObesityWeek @ObesityWeek #OW2026 omadahealth.com/resource-cen…
3
4
336
Our research team is at #ObesityWeek with two new studies on support between doctor visits. 71% of our GLP-1 Care Track members stayed on their GLP-1 for a year, and those who did lost an average of 18.4% of body weight. @ObesityWeek #OW2026 omadahealth.com/resource-cen…
1
223
74% of insured U.S. adults have a condition Omada can treat.
From diabetes and hypertension to musculoskeletal conditions, Omada is aiming to bend the curve on some of the most common chronic conditions affecting Americans today.
$OMDA
1
5
324
We’re proud to share the financial results from our strongest quarter yet!
Omada’s Q3 2026 results reflected continued demand across our integrated cardiometabolic care platform with our diabetes and hypertension programs leading the charge in year-over-year growth.
Highlights from Q3:
📈 Revenue grew 34% year-over-year to $91 million
📊 Gross margin of 76% in the third quarter, up from 66% in Q3 2025
↗️ Non-GAAP gross margin of 78% in the third quarter, up from 68% in Q3 2025
⬆️ Net income of $7 million in the third quarter, compared with net loss of $3 million in Q3 2025
💫 Adjusted EBITDA of $12 million in the third quarter, compared with adjusted EBITDA of $2 million in Q3 2025
👥 Total Members increased 36% YoY
In addition, at the end of Q3, average tenure in our program reached a record of roughly 2 years and 4 months, demonstrating the impact and scalability of our cardiometabolic platform. The longer a member can remain in the program, the greater the opportunity to reach their milestones and live healthier lives.
Learn more in our Q3 2026 release below with GAAP to non-GAAP reconciliation:
investors.omadahealth.com/ne…
$OMDA
What powers Omada?
➡️ Clinical evidence shapes commercial strategy
➡️ Technology scales our services and lowers costs
➡️ Human coaching fuels engagement and quality
➡️ Outcomes guide innovation
Together, these create a cycle of innovation, with our members always at the center.
$OMDA
238
Omada’s Clinical Research Scientist Lisa Stanton, PhD, takes the stage at @world_obesity for an oral presentation on a question coming up more often in GLP-1 care: how to improve the quality of weight loss, along with the amount.
She'll walk through Omada's 12-week comparative study, recently published in the Journal of Diabetes, Obesity and Metabolism. On average, people in Omada's GLP-1 Care Track reduced body fat percentage about twice as much as those receiving standard care.
Learn more: ow.ly/BZ6A50ZZaQt
1
1
230
Today at our Investor Day, we are introducing updated long-term financial targets: 80% non-GAAP gross margin, 30% adjusted EBITDA margin, and continued annual revenue growth of at least 20%.
The webcast begins at 1pm ET. Learn more here: ow.ly/wKVY50ZM3jX
$OMDA
A new independent model from @globaldataplc estimates up to $11,142 in cumulative per-member savings for Omada's GLP-1 program at five years, driven by medication persistence, engagement, and disease-risk reduction.
Read more: ow.ly/yvPO50ZLzsT
🚨New peer-reviewed study alert! Omada’s latest publication examined the impact of our diabetes program combined with wearable continuous glucose monitoring (CGM) technology. Spoiler: Omada + CGM tech = a potent product. Read the full study here: omadahealth.com/resource-cen…
333
$OMDA Q2 2026 highlights:
📈 $88M revenue (+43% YoY)
📊 73% gross margin
💫 $11M adjusted EBITDA
👥 Total Members +45% YoY
Our most profitable quarter to date.
investors.omadahealth.com/ne…
Health plans are closer to a dynamic that isn’t always visible elsewhere: as GLP‑1 demand grows, so do point solutions. The result is fragmented care—and diminishing returns for plans and members alike.
1
1
273
With the GLP-1 landscape rapidly evolving, benefit consultants are navigating new concerns raised by their clients. What if limiting access creates employee friction? What if utilization spikes faster than expected? What if coverage decisions change?
4
1
245
Learn more about how Omada’s GLP-1 program turns that kind of recommendation into durable outcomes at scale. omadahealth.com/resource-cen…
1
56
What would it look like to recommend a single partner that can flex across the variability you’re seeing with clients?
33
The moment calls for a partner built for change; one that allows you to make a recommendation that holds up as conditions shift, without asking clients to choose between cost control and employee support.
20
These pressures go beyond a simple cover vs. don’t cover decision. They can cause clients to weigh runaway pharmacy costs against facing employee backlash when coverage isn’t offered, along with the reality that weight health needs may go unmet.
64
We recently hosted the webinar “The Story Between Visits: A New Lens on Cardiometabolic Care.” Here’s how MercerWell’s Tylane Garrett framed the stakes: "Employers should be wary of fragmented solutions that leave members to piece together their own care."
benefitnews.com/web-seminars…
173
The question right now isn’t just whether to cover GLP‑1s—it’s defining the right path for your organization. What matters is having a strategy that can meet the moment, balancing how you approach coverage with how you support people seeking GLP‑1s.
3
176
Want to know more? Here’s a good place to start. omadahealth.com/omada-for-gl… #EmployerHealth
#GLP1Benefits
37















